Approximately 10% of neuroblastoma harbor mutations in the anaplastic lymphoma kinase (ALK) receptor tyrosine kinase (RTK), providing an important therapeutic target (Trigg and Turner, 2018). The gene discussed is ALK; the disease is neuroblastoma.